Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Chonluten
Also known as: Glu-Asp-Gly, EDG
Chonluten is a synthetic tripeptide (Glu-Asp-Gly) developed as a bronchial and lung tissue bioregulator in the Khavinson system. It is proposed to normalize respiratory epithelial function and support lung tissue repair. Evidence is limited to a handful of in vitro experiments and small, uncontrolled Russian clinical observations.
Risk Level
Low RiskDifficulty
Intermediate| Molecular Formula | C11H17N3O8 |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Proposed to regulate gene expression in bronchial epithelial cells, promoting normal differentiation and function of respiratory tissue. In vitro data suggests modulation of proliferation and protein synthesis in lung fibroblasts and bronchial mucosal cells.
Dosing Research
Oral capsules: 10 mg 1-2 times daily for 10-30 days. Some sublingual protocols exist. Often combined with immune-supporting bioregulators in respiratory health protocols. Courses repeated every 3-6 months.
Side Effects & Risks
No adverse effects reported in limited available literature. Rapid degradation of this short peptide limits both efficacy and toxicity potential. No controlled human safety data exists.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.